95% of domestically produced drugs are imitated 2 years later, the generic drug market may reach 500 billion

With the expiration of a large number of foreign patent drugs and the loosening of domestic policies, China's generic pharmaceutical industry is ushering in an unprecedented "opportunity period" By 2015, the market size may be close to 500 billion yuan However, this does not mean that domestic pharmaceutical enterprises can live a comfortable life, and there is still a huge gap in the factors such as backward technological capabilities and industrial development Domestic pharmaceutical companies have been seizing the high margin generic drugs, facing the "patent cliff" of foreign pharmaceutical companies Chinese generic drugs have been waiting for the opening of the market At present, China has been able to produce some bio generic drugs Of the 13 categories of 25 genetic engineering drugs and vaccine products with different specifications approved for marketing, 6 categories of 9 products with 21 specifications belong to the original, and the rest belong to the imitation Most of the more than 100 varieties of biopharmaceuticals under study in China are improved imitations According to the data, the proportion of biopharmaceutical output value in total pharmaceutical output value has increased from 7.91% in 2006 to 16.1% in 2011, while the proportion of profit has increased from 10.3% in 2006 to 13.7% In terms of drug types, McAb has shown good effect and market acceptance in the treatment of cancer, rheumatoid and other diseases It is worth noting that in addition to pharmaceutical enterprises, more and more investment institutions have also found opportunities for bio generic drugs Recently, Hebei Gu'an peptide Valley Life Science Park invested and constructed by Huaxia happiness foundation Co., Ltd officially opened Through cooperation with enterprises and institutions in the biopharmaceutical industry chain, the park tries to integrate the innovative elements of the biopharmaceutical industry, establish an incubation acceleration system, and promote the research and development of bio generic drugs in China Related research report on generic drugs 2013-2018 analysis report on the development prospect and investment trend of the generic industry 2013-2017 research and consultation report on the competitive pattern and investment value of the generic industry 2009-2014 research and forecast analysis report on the global generic market 2008-2010 in-depth research and investment consultation report on the global generic market 2006 analysis and 2011 Development forecast research report more pharmaceutical industry analysis regulatory standards are too low and the technology is inherently weak attractive market prospects can not be converted into real profit statements If Chinese pharmaceutical companies want to catch up with the spring of generic drugs, they need to prepare in many aspects, such as external environment and internal strength In addition to the patent system to be broken, China's drug quality supervision and a series of indicators need to be improved Generic drugs are not just fake products In the international market, countries have strict requirements for generic drugs China is a big country of generic drugs, but it is far from a big country of generic drugs The common self-identity of Chinese pharmaceutical industry is: "there is a large gap between the quality of some generic drugs in China and the international advanced level.